IG17104 - Pan-European Educational Platform on Multidrug Resistant Tumours and Personalised Cancer Treatment
Multidrug resistance (MDR) affects 30 to 60% of cancer patients, causing poor quality of life and high costs for healthcare systems. Research in the MDR field is highly fragmented, and there is no professional figure of young scientists that are adequately instructed in the different disciplines, trained to have interdisciplinary and transdisciplinary views and approaches that cover preclinical and clinical research in MDR tumours in order to successfully develop diagnostic tests or new drugs for MDR tumours. This CIG aims to create this new professional figure. By exploiting the scientific excellence present in our COST Action and the experience accumulated in organising training schools, practical-theoretical courses and workshops for young scientists, the CIG aims to create a prototype for a training platform that will allow each scientist to fill the gaps in her/his scientific knowledge, and acquire a broader set of skills and expertise that will be advantageous at multiple levels.
